6JU0 Stock Overview
A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
BioCardia, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.78 |
52 Week High | US$18.45 |
52 Week Low | US$0.15 |
Beta | 1.36 |
11 Month Change | 0% |
3 Month Change | 12.24% |
1 Year Change | -56.03% |
33 Year Change | -86.99% |
5 Year Change | n/a |
Change since IPO | -81.14% |
Recent News & Updates
Recent updates
Shareholder Returns
6JU0 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -0.7% | -0.02% |
1Y | -56.0% | -17.2% | 8.2% |
Return vs Industry: 6JU0 underperformed the German Biotechs industry which returned -19.7% over the past year.
Return vs Market: 6JU0 underperformed the German Market which returned 4.9% over the past year.
Price Volatility
6JU0 volatility | |
---|---|
6JU0 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6JU0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6JU0's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 18 | Peter Altman | www.biocardia.com |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
BioCardia, Inc. Fundamentals Summary
6JU0 fundamental statistics | |
---|---|
Market cap | €5.27m |
Earnings (TTM) | -€7.66m |
Revenue (TTM) | €383.23k |
13.7x
P/S Ratio-0.7x
P/E RatioIs 6JU0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6JU0 income statement (TTM) | |
---|---|
Revenue | US$428.00k |
Cost of Revenue | US$5.07m |
Gross Profit | -US$4.64m |
Other Expenses | US$3.92m |
Earnings | -US$8.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.03 |
Gross Margin | -1,084.35% |
Net Profit Margin | -1,999.77% |
Debt/Equity Ratio | 0% |
How did 6JU0 perform over the long term?
See historical performance and comparison